文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

酪氨酸激酶抑制剂与人类表皮生长因子受体2阳性乳腺癌

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer.

作者信息

Abunada Aya, Sirhan Zaid, Thyagarajan Anita, Sahu Ravi P

机构信息

Department of Pharmacy, Sidra Medicine, Doha 0000, Qatar.

Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States.

出版信息

World J Clin Oncol. 2023 May 24;14(5):198-202. doi: 10.5306/wjco.v14.i5.198.

DOI:10.5306/wjco.v14.i5.198
PMID:37275938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10236985/
Abstract

The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.

摘要

在过去十年中，针对乳腺癌（BC）患者开展的人表皮生长因子受体2（HER2）导向治疗的证据越来越多。最近，酪氨酸激酶抑制剂（TKIs）在人类恶性肿瘤治疗中的应用备受关注。这篇文献评论旨在强调与广泛研究的TKI药物相关的最新发现及其在改善HER2阳性乳腺癌治疗结果方面的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7b/10236985/ba72f755f7b7/WJCO-14-198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7b/10236985/ba72f755f7b7/WJCO-14-198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7b/10236985/ba72f755f7b7/WJCO-14-198-g001.jpg

相似文献

[1]
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer.

World J Clin Oncol. 2023-5-24

[2]
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.

NPJ Breast Cancer. 2021-5-20

[3]
Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.

Medicine (Baltimore). 2020-12-18

[4]
Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.

Breast Care (Basel). 2020-12

[5]
Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.

Ther Adv Med Oncol. 2022-3-24

[6]
Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.

Front Pharmacol. 2022-12-12

[7]
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.

Cancer Res Treat. 2020-10

[8]
The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.

Eur J Cancer. 2021-9

[9]
Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.

Front Oncol. 2021-12-16

[10]
Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Am J Cancer Res. 2019-10-1

引用本文的文献

[1]
Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.

Am J Cancer Res. 2024-9-15

[2]
CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells.

J Biomed Sci. 2024-10-15

本文引用的文献

[1]
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.

JAMA Oncol. 2023-2-1

[2]
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.

Target Oncol. 2022-5

[3]
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.

Breast Cancer Res Treat. 2021-10

[4]
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.

Future Oncol. 2021-11

[5]
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.

Breast Cancer Res Treat. 2021-8

[6]
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.

NPJ Breast Cancer. 2021-5-20

[7]
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

Lancet Oncol. 2021-3

[8]
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

Clin Cancer Res. 2021-2-1

[9]
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer.

Technol Cancer Res Treat. 2020

[10]
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.

J Clin Pharmacol. 2021-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索